The expanding role of stereotactic body radiation therapy in oligometastatic solid tumors: What do we know and where are we going?

Journal Article (Review)

The spectrum hypothesis posits that there are distinct clinical states of metastatic progression. Early data suggest that aggressive treatment of more biologically indolent metastatic disease, characterized by metastases limited in number and destination organ, may offer an opportunity to alter the disease course, potentially allowing for longer survival, delay of systemic therapy, or even cure. The development of stereotactic body radiation therapy (SBRT) has opened new avenues for the treatment of oligometastatic disease. Early data support the use of SBRT for treating oligometastases in a number of organs, with promising rates of treated metastasis control and overall survival. Ongoing investigation is required to definitively establish benefit, determine the appropriate treatment regimen, refine patient selection, and incorporate SBRT with systemic therapies.

Full Text

Duke Authors

Cited Authors

  • Hong, JC; Salama, JK

Published Date

  • January 2017

Published In

Volume / Issue

  • 52 /

Start / End Page

  • 22 - 32

PubMed ID

  • 27886588

Electronic International Standard Serial Number (EISSN)

  • 1532-1967

International Standard Serial Number (ISSN)

  • 0305-7372

Digital Object Identifier (DOI)

  • 10.1016/j.ctrv.2016.11.003

Language

  • eng